BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11583066)

  • 1. Glatiramer acetate in the treatment of multiple sclerosis.
    Sela M; Teitelbaum D
    Expert Opin Pharmacother; 2001 Jul; 2(7):1149-65. PubMed ID: 11583066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copolymer 1: from basic research to clinical application.
    Teitelbaum D; Arnon R; Sela M
    Cell Mol Life Sci; 1997 Jan; 53(1):24-8. PubMed ID: 9117994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
    Dhib-Jalbut S
    Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
    Carter NJ; Keating GM
    Drugs; 2010 Aug; 70(12):1545-77. PubMed ID: 20687620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy with glatiramer acetate for multiple sclerosis.
    Munari L; Lovati R; Boiko A
    Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate for multiple sclerosis.
    La Mantia L; Munari LM; Lovati R
    Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
    Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
    CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific vaccines against autoimmune diseases.
    Sela M
    C R Acad Sci III; 1999 Nov; 322(11):933-8. PubMed ID: 10646086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cop 1 as a candidate drug for multiple sclerosis.
    Teitelbaum D; Arnon R; Sela M
    J Neural Transm Suppl; 1997; 49():85-91. PubMed ID: 9266417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
    Scott LJ
    CNS Drugs; 2013 Nov; 27(11):971-88. PubMed ID: 24129744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; OberyƩ J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.